Anlotinib Retrospective Study for Esophageal Cancer

Efficacy and Safety of Anlotinib in the First-line or Second-line Treatment of Locally Advanced or Metastatic Esophageal Cancer in China, a Retrospective, Multicenter, Real-world Study

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT05303740

Enrollment

300

Registered

2022-03-31

Start date

2019-01-01

Completion date

2022-03-01

Last updated

2022-03-31

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Esophageal Neoplasms

Brief summary

The efficacy of anlotinib in the treatment of esophageal cancer has been confirmed. The purpose of this study was to retrospectively observe the efficacy and safety of anlotinib in the first and second line of advanced esophageal cancer in the real world.

Interventions

DRUGAnlotinib

This is an observational study.

Study design

Observational model

COHORT

Time perspective

RETROSPECTIVE

Eligibility

Sex/Gender

ALL

Healthy volunteers

Inclusion criteria

* Esophageal cancer diagnosed pathologically or clinically * Patients who use anlotinib alone, or combined with chemoradiotherapy, or plus PD-1 inhibitors in first-line or second-line treatment

Exclusion criteria

None

Design outcomes

Primary

Measure	Time frame	Description
PFS	From date of admission until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 24 months	Progression Free Survival

Secondary

Measure	Time frame	Description
OS	From date of admission until the date of death from any cause, assessed up to 24 months	Overall Survival

Countries

China

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026